ProPhase Labs Inc (NASDAQ:PRPH) Director Jason Michael Barr purchased 8,500 shares of ProPhase Labs stock in a transaction on Thursday, August 15th. The stock was bought at an average cost of $2.05 per share, for a total transaction of $17,425.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
PRPH stock traded up $0.07 during mid-day trading on Friday, reaching $2.04. The company had a trading volume of 1,570 shares, compared to its average volume of 5,203. The firm has a fifty day simple moving average of $2.06 and a 200 day simple moving average of $2.77. ProPhase Labs Inc has a fifty-two week low of $1.97 and a fifty-two week high of $4.00.
ProPhase Labs (NASDAQ:PRPH) last issued its earnings results on Monday, August 12th. The company reported ($0.11) earnings per share for the quarter. ProPhase Labs had a negative return on equity of 21.71% and a negative net margin of 35.98%. The business had revenue of $1.65 million for the quarter.
Separately, TheStreet lowered ProPhase Labs from a “c-” rating to a “d+” rating in a research report on Tuesday, July 9th.
ProPhase Labs Company Profile
ProPhase Labs, Inc engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter(OTC) consumer healthcare products, dietary supplements, and other remedies in the United States. The company offers TK Supplements product line include Legendz XL for sexual health; Triple Edge XL, an energy booster and testosterone support; and Super ProstaFlow+ for prostate and urinary health.
Featured Story: What does an inverted yield curve signify?
Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.